Loading
The brain is the weak point of HER2-positive breast cancer: antibodies control the rest of the body but cross poorly into the brain, so up to half of patients with advanced disease develop brain metastases. Tucatinib with trastuzumab and capecitabine was the first drug proven to help, and trastuzumab deruxtecan shrinks brain lesions in most patients.
Brain metastases became the signature problem of HER2-positive disease once trastuzumab began to control it elsewhere: antibodies are too large to cross an intact blood-brain barrier, so the brain was often the first and only site of progression. Lesions present with headache, seizures or focal deficits, or are found on staging MRI; guidelines do not recommend routine screening MRI, though the landmark trials required it. Local treatment follows the number and size of lesions: stereotactic radiosurgery for a limited number, which the Alliance N0574 trial showed preserves cognition better than adding whole-brain radiotherapy, surgery for a large symptomatic lesion, and whole-brain radiotherapy held back for many lesions or leptomeningeal spread.
HER2CLIMB was the first randomised trial to enrol patients with active, untreated brain metastases and prove a drug helps them. It randomised 612 women who had received trastuzumab, pertuzumab and trastuzumab emtansine, almost half with brain metastases, to tucatinib or placebo with trastuzumab and capecitabine: progression-free survival rose from 5.6 to 7.8 months (hazard ratio 0.54), overall survival from 17.4 to 21.9 months (hazard ratio 0.66), and the risk of intracranial progression fell by about two thirds, leading to approval in April 2020. Earlier, lapatinib with capecitabine had shown intracranial responses in the single-arm LANDSCAPE study, and neratinib reduced the need for brain interventions in NALA; HER2CLIMB-02 later added tucatinib to trastuzumab emtansine with a modest gain concentrated in patients with brain disease, and HER2CLIMB-05 in 2025 showed tucatinib added to first-line antibody maintenance delays progression by more than eight months.
Trastuzumab deruxtecan then showed that an antibody-drug conjugate can work inside the brain. Small phase 2 studies (TUXEDO-1, DEBBRAH) reported high intracranial response rates, and DESTINY-Breast12 treated 504 patients, 263 with brain metastases, with an intracranial objective response in 71.7 percent and 61.6 percent of the brain-metastasis cohort progression-free at twelve months, including patients whose lesions had not been irradiated. Because trastuzumab deruxtecan is also the second-line standard after DESTINY-Breast03, and first line with pertuzumab after DESTINY-Breast09, many patients now receive brain-active systemic therapy before the brain is ever involved. Whether systemic therapy should replace radiotherapy first in selected asymptomatic patients, how to treat leptomeningeal disease, and the risk of radionecrosis when radiosurgery and antibody-drug conjugates are combined are the open questions.
Averages across everyone diagnosed, often years ago. A median is the middle of a group: half the people counted lived longer than the figure shown, and some lived far longer. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
Up to half of women with metastatic HER2-positive breast cancer develop brain metastases during their illness, more than in any other breast subtype, partly because HER2 antibodies control disease elsewhere while the brain remains a sanctuary.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Basal-like 2 triple-negative breast cancer (BL2), Mesenchymal triple-negative breast cancer (M), Mesenchymal stem-like triple-negative breast cancer (MSL), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive cribriform carcinoma of the breast, Invasive micropapillary carcinoma of the breast, Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Stereotactic radiosurgery to each lesion, or surgery for a large symptomatic lesion, followed by HER2-directed systemic therapy; whole-brain radiotherapy reserved for many lesions.
Tucatinib with trastuzumab and capecitabine (HER2CLIMB), which improved survival and delayed brain progression.
Trastuzumab deruxtecan, with intracranial responses in most patients (DESTINY-Breast12), positioned as second-line therapy after DESTINY-Breast03.
Tucatinib added to trastuzumab and pertuzumab maintenance after induction chemotherapy (HER2CLIMB-05).
Neratinib or lapatinib with capecitabine, trastuzumab emtansine with tucatinib (HER2CLIMB-02), repeat radiosurgery, or a clinical trial.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Trastuzumab deruxtecan is an option for active HER2-positive brain metastases, complementing tucatinib-based therapy, and challenges the assumption that antibody-drug conjugates cannot reach the brain.
This analysis is the evidence base for treating active HER2-positive brain metastases with a systemic regimen, sometimes deferring radiotherapy, and for tucatinib's brain-specific labelling.
Tucatinib-based therapy is the standard for HER2-positive disease with active brain metastases and a standard later-line option overall; it was the first trial to enrol progressing brain metastases and show a systemic drug helps them.
Query for this cancer: (TITLE:"HER2-positive breast cancer with brain metastases" OR ABSTRACT:"HER2-positive breast cancer with brain metastases" OR TITLE:"HER2-positive brain metastases" OR ABSTRACT:"HER2-positive brain metastases" OR TITLE:"Central nervous system metastases from HER2-positive breast cancer" OR ABSTRACT:"Central nervous system metastases from HER2-positive breast cancer" OR TITLE:"Intracranial HER2-positive disease" OR ABSTRACT:"Intracranial HER2-positive disease") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about HER2-positive breast cancer with brain metastases, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
Bleeding that does not stop by itself, bleeding from more than one site, or new bruising in several places or one large area.
Temperature of 38 C or higher, or feeling shivery and unwell even without a fever. Antibody-drug conjugates suppress the bone marrow, and several carry a boxed warning for severe neutropenia.
Any new or worsening cough, breathlessness or fever. The label says to interrupt treatment for any suspected ILD and to permanently discontinue for grade 2 or higher.
CYP3A4: Tucatinib (strong inhibitor) raises Lapatinib exposure (sensitive substrate).. Avoid; if unavoidable, reduce to 500 mg daily.
CYP3A4: Tucatinib (strong inhibitor) raises Neratinib exposure (sensitive substrate).. Avoid strong and moderate inhibitors.
See all on the product pages:CapecitabineLapatinibNeratinibTrastuzumab deruxtecanTrastuzumab emtansineTucatinib·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with HER2-positive breast cancer with brain metastases, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.